76 related articles for article (PubMed ID: 11889677)
21. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
22. [Imatinib].
Urabe A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
[TBL] [Abstract][Full Text] [Related]
23. Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW; O'Brien SG; Ford JM; Druker BJ
J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
[TBL] [Abstract][Full Text] [Related]
24. Cardiotoxicity of imatinib: At the heart of the problem.
Tiribelli M; Medeot M
Leuk Res; 2011 Jan; 35(1):36-7. PubMed ID: 20970188
[No Abstract] [Full Text] [Related]
25. Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient.
Fava P; Stroppiana E; Savoia P; Bernengo MG
J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):244-5. PubMed ID: 19694892
[No Abstract] [Full Text] [Related]
26. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
27. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
28. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
Mathy A; Baas P; Dalesio O; van Zandwijk N
Lung Cancer; 2005 Oct; 50(1):83-6. PubMed ID: 15951053
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
30. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
31. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Singh T; Casson C
Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
[TBL] [Abstract][Full Text] [Related]
32. Catastrophic tumour lysis syndrome following single dose of imatinib.
Keane C; Henden A; Bird R
Eur J Haematol; 2009 Mar; 82(3):244-5. PubMed ID: 19067739
[No Abstract] [Full Text] [Related]
33. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
Mcpherson T; Sherman V; Turner R
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
[No Abstract] [Full Text] [Related]
34. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
35. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
[TBL] [Abstract][Full Text] [Related]
36. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.
Porta C; Mutti L; Tassi G
Cancer Chemother Pharmacol; 2007 Jan; 59(1):149-50. PubMed ID: 16636799
[No Abstract] [Full Text] [Related]
37. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
38. Lymphomatoid granulomatosis induced by imatinib-treatment.
Yazdi AS; Metzler G; Weyrauch S; Berneburg M; Bitzer M; Müller-Hermelink HK; Röcken M
Arch Dermatol; 2007 Sep; 143(9):1222-3. PubMed ID: 17875901
[No Abstract] [Full Text] [Related]
39. Cutaneous Lichenoid dermatitis associated with imatinib mesylate.
Chan CY; Browning J; Smith-Zagone MJ; Martinelli PT; Hsu S
Dermatol Online J; 2007 May; 13(2):29. PubMed ID: 17498448
[No Abstract] [Full Text] [Related]
40. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Ault P; Kantarjian H; Welch MA; Giles F; Rios MB; Cortes J
Leuk Res; 2004 Jun; 28(6):613-8. PubMed ID: 15120938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]